سعر فوليتروب 150 وحدة دولية فيال 2022

Recombinant human follicle-stimulating hormone (follitropin) 150 IU vial for injection, a gonadotropin used for ovarian stimulation in female infertility treatment.

• Most common: headache, ovarian cysts and injection-site reactions (pain, erythema, haematoma, swelling, irritation). Mild or moderate OHSS is common; severe OHSS is uncommon; thromboembolism very rare.General active-ingredient information · European Medicines Agency

• Hypersensitivity to follitropin alfa or excipients; tumours of the hypothalamus or pituitary gland; ovarian enlargement or cyst not due to polycystic ovarian disease; gynaecological haemorrhage of unknown origin; ovarian, uterine or mammary carcinoma.General active-ingredient information · European Medicines Agency
• Must not be used when an effective response cannot be obtained, e.g. primary ovarian failure, malformations of sexual organs or uterine fibroids incompatible with pregnancy, primary testicular insufficiency.General active-ingredient information · European Medicines Agency

• Potent gonadotropin; use only by physicians experienced in infertility management. Ovarian hyperstimulation syndrome (OHSS) can occur and may become serious; adhere to the dose regimen, monitor with ultrasound and serum estradiol, and withhold hCG if hyperstimulation occurs.General active-ingredient information · European Medicines Agency
• Increased risk of multiple pregnancy, pregnancy loss and ectopic pregnancy versus natural conception; thromboembolic events may occur, especially with risk factors; patients with porphyria should be monitored closely.General active-ingredient information · European Medicines Agency

• hCG, clomiphene citrate (other ovulation stimulants)Concomitant use may potentiate the follicular response.European Medicines Agency
• GnRH agonists or antagonistsPituitary desensitisation may increase the follitropin dose needed for an adequate ovarian response.European Medicines Agency

• No indication for use during pregnancy; limited data (fewer than 300 pregnancy outcomes) show no malformative or feto/neonatal toxicity, but clinical data are insufficient to exclude a teratogenic effect.General active-ingredient information · European Medicines Agency
• Not indicated during breast-feeding.General active-ingredient information · European Medicines Agency

• Monitor ovarian response with ultrasound, preferably combined with serum estradiol measurement; use the lowest effective dose.General active-ingredient information · European Medicines Agency

• Follitropin alfa (recombinant human FSH): Recombinant follicle-stimulating hormone; FSH stimulates the development of ovarian follicles, while LH is involved in follicle development, steroidogenesis and maturation.